BioNTech SE (NASDAQ:BNTX – Get Rating) – Investment analysts at SVB Leerink cut their FY2022 earnings per share (EPS) estimates for shares of BioNTech in a report issued on Tuesday, August 9th. SVB Leerink analyst D. Graybosch now expects that the company will post earnings of $33.38 per share for the year, down from their prior estimate of $39.49. SVB Leerink currently has a "Outperform" rating and a $224.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is $35.28 per share. SVB Leerink also issued estimates for BioNTech's Q4 2022 earnings at $9.93 EPS, Q1 2023 earnings at $6.36 EPS, Q3 2023 earnings at $4.09 EPS, FY2023 earnings at $22.16 EPS and Q1 2024 earnings at ($0.01) EPS.

Get BioNTech alerts:

Several other research analysts have also recently issued reports on BNTX. Jefferies Financial Group set a $230.00 price target on BioNTech in a research note on Monday, May 9th. Morgan Stanley cut their price objective on BioNTech from $195.00 to $194.00 and set an "equal weight" rating for the company in a report on Friday, July 15th. Canaccord Genuity Group restated a "buy" rating and issued a $192.00 price objective on shares of BioNTech in a report on Wednesday, July 6th. Canaccord Genuity Group upped their price objective on BioNTech from $192.00 to $200.00 and gave the company a "buy" rating in a report on Tuesday. Finally, HC Wainwright cut their price objective on BioNTech from $283.00 to $272.00 and set a "buy" rating for the company in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and an average target price of $235.62.

BioNTech Price Performance

Shares of BNTX opened at $158.59 on Thursday. BioNTech has a 12 month low of $117.08 and a 12 month high of $391.57. The company has a market cap of $38.54 billion, a P/E ratio of 3.06 and a beta of -0.08. The stock has a fifty day moving average price of $154.63 and a 200 day moving average price of $157.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.15 and a quick ratio of 4.93.

BioNTech (NASDAQ:BNTX – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported $6.45 EPS for the quarter, missing analysts' consensus estimates of $7.08 by ($0.63). The company had revenue of $3.20 billion for the quarter, compared to the consensus estimate of $4.11 billion. BioNTech had a return on equity of 88.76% and a net margin of 55.43%. BioNTech's quarterly revenue was down 39.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $12.98 earnings per share.

Institutional Trading of BioNTech

Hedge funds have recently made changes to their positions in the company. KRS Capital Management LLC acquired a new position in BioNTech in the fourth quarter valued at approximately $25,000. Koshinski Asset Management Inc. bought a new stake in shares of BioNTech during the first quarter valued at approximately $26,000. Covestor Ltd bought a new stake in shares of BioNTech during the fourth quarter valued at approximately $47,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of BioNTech by 66.7% during the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 250 shares of the company's stock valued at $43,000 after acquiring an additional 100 shares in the last quarter. Finally, DeDora Capital Inc. bought a new stake in shares of BioNTech during the first quarter valued at approximately $51,000. 14.42% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Stories

• Get a free copy of the StockNews.com research report on BioNTech (BNTX)
• Look at Honeywell for a Steady and Diversified Stock
• Why Invest in High-Yield Dividend Stocks?
• Find and Profitably Trade Stocks at 52-Week Lows
• Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
• Solar Stocks Shine Brightly After Passage Of Clean Energy Bill

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.